Mohammad Nasser Alkhrayef

Dr. Mohammad Nasser Alkhrayef


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MFMohannad M. Fallatah
Mohannad M. Fallatah
IAIbrahim Alradwan
Ibrahim Alradwan
NFNojoud AL Fayez
Nojoud AL Fayez
AAAlhassan Aodah
Alhassan Aodah
MAMohammad Nasser Alkhrayef
Mohammad Nasser Alkhrayef
Yahya F. JamousYahya F. Jamous
Yahya F. Jamous
Cancer treatment has undergone a paradigm shift following the introduction of novel cancer treatment approaches that involve the host’s immune system in fighting established tumors. This new concept aids the immune system in identifying, attacking, and killing the tumor cells. However, although some encouraging results were observed clinically, this approach has its own limitations. For example, the benefits of certain anticancer drugs were only observed in some patients, off-target effects, immune evasion, and poor pharmacokinetics. Recently, several advancements have been made with the understanding and development of tumor-targeted drug delivery systems, which combine both effectiveness and patients’ safety during cancer treatment. In this review, we will focus on the latest progress in targeted drug delivery, particularly applying nanoparticles, liposomes, exosomes, and Wharton’s jelly-derived macrovesicles as immune cell enhancers, as well as overcoming therapeutic resistance. We also characterize major current problems, such as the biocompatibility and scalability of the delivered engineering systems, as well as the required regulations. Lastly, we will show some examples of effective approaches to resolve these issues for more efficient cancer therapy. The importance of this article lies in bridging two sides in a single framework perspective: the novel implementation of unique delivery systems and the latest advances in the field of cancer immunotherapy. Thus, this provides better insights for the future of cancer treatment.

4 August 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MAMeshael Alturki
Meshael Alturki
AAAbdullah Alshehri
Abdullah Alshehri
AAAhmad Mohammad Aldossary
Ahmad Mohammad Aldossary
MFMohannad M. Fallatah
Mohannad M. Fallatah
FAFahad Almughem
Fahad Almughem
ETEssam Tawfik
Essam Tawfik
Conventional immunotherapy, including immune checkpoint blockade and chimeric antigen receptor (CAR)-T cells, has revolutionized cancer therapy over the past decade. Yet, the efficacy of these therapies is limited by tumor resistance, antigen escape mechanisms, poor persistence, and T-cell exhaustion, particularly in the treatment of solid tumors. The emergence of unconventional immunotherapies offers novel opportunities by leveraging diverse immune cell subsets and synthetic biologics. This review explores various immunotherapy platforms, including gamma delta T cells, invariant natural killer T cells, mucosal-associated invariant T cells, engineered regulatory T cells, and universal CAR platforms. Additionally, it expands on biologics, including bispecific and multispecific antibodies, cytokine fusions, agonists, and oncolytic viruses, showcasing their potential for modular engineering and off-the-shelf applicability. Distinct features of unconventional platforms include independence from the major histocompatibility complex (MHC), tissue-homing capabilities, stress ligand sensing, and the ability to bridge adaptive and innate immunity. Their compatibility with engineering approaches highlights their potential as scalable, efficient, and cost-effective therapies. To overcome translational challenges such as functional heterogeneity, immune exhaustion, tumor microenvironment-mediated suppression, and limited persistence, novel strategies will be discussed, including metabolic and epigenetic reprogramming, immune cloaking, gene editing, and the utilization of artificial intelligence for patient stratification. Ultimately, unconventional immunotherapies extend the therapeutic horizon of cancer immunotherapy by breaking barriers in solid tumor treatment and increasing accessibility. Continued investments in research for mechanistic insights and scalable manufacturing are key to unlocking their full clinical potential.

18 December 2025 in Diseases
Verified
Journal Article
Open access
PDF file
GGGhadeer Al Ghareeb
Ghadeer Al Ghareeb
ZAZaenab Mohammed Alkhair
Zaenab Mohammed Alkhair
ZAZainab Ali ALradwan
Zainab Ali ALradwan
HQHussain Mohammed Al Qaissoom
Hussain Mohammed Al Qaissoom
HSHoriah Ali Soumel
Horiah Ali Soumel
IAIbrahim Alradwan
Ibrahim Alradwan
Background: Non-communicable diseases (NCDs) such as cardiovascular diseases, diabetes, obesity, and cancer are the leading cause of mortality globally and in Saudi Arabia, accounting for more than 70% of all deaths. Despite national initiatives offering free preventive services, screening uptake remains low. This study aimed to describe the demographic and clinical characteristics of individuals participating in community-based NCD screening campaigns in the Eastern Province of Saudi Arabia and to evaluate screening uptake, compliance, and diagnostic outcomes. Methods: A retrospective cross-sectional analysis was conducted among 3106 adults screened at volunteer-driven community campaigns held between January 2023 and December 2024. Screening included anthropometric measurements, blood pressure assessment, and glucose testing, followed by eligibility evaluation for osteoporosis and cancer screening. Uptake and compliance were verified using electronic health records. Descriptive and inferential statistical analyses were applied. Results: Participants were 64% male and 36% female, with a mean age of 41.4 ± SD years. Obesity, hypertension, and diabetes were identified in 32%, 31%, and 12% of participants overall. Gender-stratified prevalence showed higher obesity among females at 36% (95% CI 32.3 to 38.1) and higher hypertension and diabetes among males at 36% (95% CI 34.0 to 38.2) and 14% (95% CI 12.1 to 15.2), respectively. Uptake among eligible individuals was 51% for dual-energy X-ray absorptiometry (DEXA), 47% for fecal immunochemical testing (FIT), 43% for Pap smear, and 39% for mammography. Diagnostic findings demonstrated substantial undetected disease burden, including osteoporosis in 41% (95% CI 26.0 to 56.8) of DEXA scans, a FIT positivity rate of 5% (95% CI 1.5 to 10.3), abnormal Pap cytology in 3% (95% CI 1.1 to 7.5), and BI-RADS 0 mammograms in 19% (95% CI 11.9 to 29.5), reflecting incomplete assessments requiring further evaluation. Conclusions: Community-based campaigns can effectively resolve limited engagement in health promotional activities and detect substantial burdens of undiagnosed NCDs. However, improvements in referral tracking, follow-up systems, and culturally tailored health education are essential to enhance screening compliance and early detection outcomes. These results can be utilized to inform public policies by extending screening services to additional areas, increasing investment in preventive health campaigns, and enhancing the capacity of the health system.

23 July 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MFMohannad M. Fallatah
Mohannad M. Fallatah
SASAMIYAH ALKHALDI
SAMIYAH ALKHALDI
DADimah K Alrabiah
Dimah K Alrabiah
IAIbrahim Alradwan
Ibrahim Alradwan
MAMohammad Nasser Alkhrayef
Mohammad Nasser Alkhrayef
AAAhmad Mohammad Aldossary
Ahmad Mohammad Aldossary
RNA vaccines have emerged as an attractive platform for treating infectious diseases, cancer immunotherapy, and personalized medicine; however, their clinical success depends on multiple factors, including efficient, stable, and scalable delivery systems. Because RNA molecules are highly sensitive to factors such as enzymatic degradation, oxidation, poor cellular uptake, and limited endosomal escape, nanocarrier platforms play essential roles in protecting RNA cargo and enabling effective intracellular delivery. The biological performance of RNA nanocarriers depends on efficient cellular uptake, endosomal escape, intracellular RNA delivery, biodistribution, and immune modulation. Comparative assessment emphasizes that lipid nanoparticles remain the most clinically mature approach, while nanostructured lipid carriers, polymeric systems, and exosome-based nanocarriers provide multiple benefits for stability, targeted delivery, biocompatibility, and/or controlled release. Translational challenges involving GMP manufacturing, batch reproducibility, regulatory expectations, and scale-up are considered critical for effective nano-based RNA vaccine delivery and are elaborated in this review. Emerging advances such as pKa-tuned ionizable lipids, ligand-targeted systems, stimuli-responsive nanocarriers, circular and self-amplifying RNA platforms, artificial intelligence-guided formulation design, and needle-free delivery technologies may further expand the safety, accessibility, and therapeutic potential of RNA vaccines. In this review, we highlight next-generation nanocarrier systems for RNA vaccines, with an emphasis on novel nanocarrier RNA vaccine delivery systems. Additionally, we evaluate stability engineering approaches that currently limit global vaccine distribution and the future of the nanocarrier platforms for RNA vaccines.

1 August 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
SASaheed Olaide Anifowose
Saheed Olaide Anifowose
MMMobarak S. Al Mosallam
Mobarak S. Al Mosallam
EBEman Abdullah Bahattab
Eman Abdullah Bahattab
FAFahad S. Alotaibi
Fahad S. Alotaibi
MAMohammad Nasser Alkhrayef
Mohammad Nasser Alkhrayef
BABADR ALDAHMASH
BADR ALDAHMASH
Plant-derived natural products are essential and prominent contributors to drug discovery, especially as anticancer agents. Medicinal plants used in alternative therapy are often obscured by poor definitions of the underlying mechanisms behind their bioactivity. In this study, we investigated the cytotoxic and mechanistic effects of an enriched bioactive fraction derived from Mondia whitei. Bioactivity-guided fractionation was performed using C18 solid-phase extraction. The cytotoxic effects were evaluated using the MTT assay, while cellular morphology and mechanistic pathways were examined through microscopy, acridine orange staining, cathepsin-based assay, and immunoblotting of apoptosis- and autophagy-related proteins. Chemical profiling of the fraction was conducted using GC–MS analysis. The enriched fraction exhibited enhanced cytotoxicity at low microgram concentrations. Morphological assessment revealed prominent cytoplasmic vacuolation, while acridine orange staining indicated the accumulation of acidic vesicles. Cathepsin-based assays and immunoblot analysis of LC3-I/II confirmed lysosomal involvement and autophagy perturbation, whereas increased p62 levels suggested disruption of the autophagy–lysosome perturbation. In parallel, activation of intrinsic apoptosis was evidenced by the increased expression of caspase-9 and caspase-3. GC–MS profiling tentatively identified lupeol and cis-vaccenic acid as the major constituents of the fraction. The results from these studies demonstrate that the enriched fraction of Mondia whitei induced vacuolation-associated cytotoxicity through autophagy–lysosome perturbation and caspase-dependent apoptosis, providing mechanistic insight into its anticancer potential.

13 November 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
FAFaisal Alagrafi
Faisal Alagrafi
SASAMIYAH ALKHALDI
SAMIYAH ALKHALDI
MAMohammad Nasser Alkhrayef
Mohammad Nasser Alkhrayef
IAIbtihal Alduhaymi
Ibtihal Alduhaymi
MAMusaad Altammami
Musaad Altammami
Yahya F. JamousYahya F. Jamous
Yahya F. Jamous
Secretory immunoglobulin A (SIgA) represents the most abundant antibody isotype at mucosal surfaces and plays a central role in maintaining intestinal immune homeostasis. In addition to its classical function in immune exclusion of pathogens, SIgA actively shapes the composition, spatial organization, and functional behavior of the gut microbiota, thereby contributing to a dynamic and reciprocal host–microbe relationship. Increasing evidence highlights that crosstalk between SIgA and the gut microbiota is not merely protective but also regulatory, influencing immune tolerance, barrier integrity, and inflammatory balance within the intestinal mucosa. This review provides a comprehensive overview of the molecular and immunological mechanisms underlying SIgA–microbiota interactions in mucosal immunity. We discuss the processes governing SIgA induction, class switching, and antigen specificity, as well as the mechanisms by which SIgA selectively coats commensal and pathogenic microorganisms. Emphasis is placed on how SIgA-mediated immune modulation shapes microbial ecology, limits immune overactivation, and maintains long-term mucosal homeostasis. Moreover, the review describes the role of dysregulation in SIgA–microbiota interactions in immune-mediated and inflammatory diseases, as well as the emerging translational perspectives. This includes the potential of SIgA-targeted strategies to modulate the gut microbiota for therapeutic benefit. By integrating mechanistic insights with clinical relevance, this review highlights SIgA–microbiota interactions at the intersection of mucosal immunology and emerging immunotherapeutic opportunities.